These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9765354)

  • 21. Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels.
    Kirsch GE; Drewe JA
    J Gen Physiol; 1993 Nov; 102(5):797-816. PubMed ID: 8301258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The binding of kappa-Conotoxin PVIIA and fast C-type inactivation of Shaker K+ channels are mutually exclusive.
    Koch ED; Olivera BM; Terlau H; Conti F
    Biophys J; 2004 Jan; 86(1 Pt 1):191-209. PubMed ID: 14695262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cumulative inactivation and the pore domain in the Kv1 channels.
    Shimizu Y; Kubo T; Furukawa Y
    Pflugers Arch; 2002 Mar; 443(5-6):720-30. PubMed ID: 11889569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3.
    Felix JP; Bugianesi RM; Schmalhofer WA; Borris R; Goetz MA; Hensens OD; Bao JM; Kayser F; Parsons WH; Rupprecht K; Garcia ML; Kaczorowski GJ; Slaughter RS
    Biochemistry; 1999 Apr; 38(16):4922-30. PubMed ID: 10213593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quinidine preferentially blocks the slow delayed rectifier potassium channel in the rested state.
    Yao JA; Trybulski EJ; Tseng GN
    J Pharmacol Exp Ther; 1996 Nov; 279(2):856-64. PubMed ID: 8930193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the mechanism by which 4-Aminopyridine occludes quinidine block of the cardiac K+ channel, hKv1.5.
    Chen FS; Fedida D
    J Gen Physiol; 1998 Apr; 111(4):539-54. PubMed ID: 9524137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A side chain in S6 influences both open-state stability and ion permeation in a voltage-gated K+ channel.
    Liu Y; Joho RH
    Pflugers Arch; 1998 Apr; 435(5):654-61. PubMed ID: 9479018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular analysis of a binding site for quinidine in a human cardiac delayed rectifier K+ channel. Role of S6 in antiarrhythmic drug binding.
    Yeola SW; Rich TC; Uebele VN; Tamkun MM; Snyders DJ
    Circ Res; 1996 Jun; 78(6):1105-14. PubMed ID: 8635242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kv1.4 channel block by quinidine: evidence for a drug-induced allosteric effect.
    Wang S; Morales MJ; Qu YJ; Bett GC; Strauss HC; Rasmusson RL
    J Physiol; 2003 Jan; 546(Pt 2):387-401. PubMed ID: 12527726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain.
    Pennington MW; Mahnir VM; Krafte DS; Zaydenberg I; Byrnes ME; Khaytin I; Crowley K; Kem WR
    Biochem Biophys Res Commun; 1996 Feb; 219(3):696-701. PubMed ID: 8645244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Model of the Block of Voltage-Gated Potassium Kv4.2 Ionic Currents by 4-Aminopyridine.
    Kehl SJ
    J Pharmacol Exp Ther; 2017 Nov; 363(2):184-195. PubMed ID: 28864468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationship studies of four novel 4-aminopyridine K
    Rodríguez-Rangel S; Bravin AD; Ramos-Torres KM; Brugarolas P; Sánchez-Rodríguez JE
    Sci Rep; 2020 Jan; 10(1):52. PubMed ID: 31919372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resolving the gating charge movement associated with late transitions in K channel activation.
    Loboda A; Armstrong CM
    Biophys J; 2001 Aug; 81(2):905-16. PubMed ID: 11463634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of 4-aminopyridine sensitivity in a human brain kv1.4 k(+) channel: phenylalanine substitutions in leucine heptad repeat region stabilize channel closed state.
    Judge SI; Yeh JZ; Goolsby JE; Monteiro MJ; Bever CT
    Mol Pharmacol; 2002 Apr; 61(4):913-20. PubMed ID: 11901231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Voltage-dependent, open channel blockade of the cardiac sarcoplasmic reticulum potassium channel by 4-aminopyridine.
    Liu QY; Rasmusson RL; Liu QX; Strauss HC
    Can J Cardiol; 1998 Feb; 14(2):275-80. PubMed ID: 9520865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An essential binding surface for ShK toxin interaction with rat brain potassium channels.
    Pennington MW; Mahnir VM; Khaytin I; Zaydenberg I; Byrnes ME; Kem WR
    Biochemistry; 1996 Dec; 35(51):16407-11. PubMed ID: 8987971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chiral aspects of drug action at ion channels: a commentary on the stereoselectivity of drug actions at voltage-gated ion channels with particular reference to verapamil actions at the Ca2+ channel.
    Kwon YW; Triggle DJ
    Chirality; 1991; 3(5):393-404. PubMed ID: 1721828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A model for 4-aminopyridine action on K channels: similarities to tetraethylammonium ion action.
    Armstrong CM; Loboda A
    Biophys J; 2001 Aug; 81(2):895-904. PubMed ID: 11463633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-Terminal deletions of rKv1.4 channels affect the voltage dependence of channel availability.
    Höllerer-Beitz G; Schönherr R; Koenen M; Heinemann SH
    Pflugers Arch; 1999 Jul; 438(2):141-6. PubMed ID: 10370099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An amino acid residue whose change by mutation affects drug binding to the HERG channel.
    Ishii K; Kondo K; Takahashi M; Kimura M; Endoh M
    FEBS Lett; 2001 Oct; 506(3):191-5. PubMed ID: 11602243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.